Production of synthetic adjuvant system (SAS): a synergistic combination of synthetic adjuvant components
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00021
- Awardee
-
Inimmune Corp UEI EF8AMXMGG8W5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,992,471
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · PHS20201 · Posted Jun 21, 2019
- Contract value 100% obligated
- $1,992,471.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Missoula, MT 59802, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,992,471 |
About this award
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in Missoula, Montana, the firm fixed price contract runs from June 2020 through May 2023. It has a total small business set aside designation and will support Inimmune's continued work in the synergistic combination of synthetic adjuvant components, as initially proposed under Phase I of the SBIR vehicle.
Quick answers
Who was awarded contract 75N93020C00021?
75N93020C00021 was awarded to Inimmune Corp by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.
How much is contract 75N93020C00021 worth?
The government has obligated $1,992,471 on 75N93020C00021.
Was contract 75N93020C00021 competed?
The extent of competition for 75N93020C00021 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award